Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGN101 vaccination in non-small-cell lung cancer
2004-004592-11Phase 2Terminated
- Sponsor
- Igeneon
- Start
- Aug 2005
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of IGN101 in non-small cell lung cancer (NSCLC), sponsored by Igeneon. Started Aug 2005; status: terminated.
02
Drugs
IGN101
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-004592-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004592-11.